Interview with Gabor Somlyai, Managing Director, HYD LLC.
You founded HYD almost 20 years ago, in 1992. Can you first explain to our readers why you made the switch from doing research at the Hungarian Institute of Oncology…
Address: Fürj u. 2. , Budapest, H-1124 Budapest,Hungary
Tel: +36 1 381 0765
Web: http://www.hyd.hu/
HYD LLC. for Cancer Research and Drug Development was established for the research, development and worldwide marketing of pharmaceutical and consumer products based on the proprietary procedure, deuterium depletion, primarily for the prevention and treatment of various kinds of cancer and for exploration of new indication fields for the application of deuterium-depleted water (DDW). Different applications of deuterium depletion are protected by international patents.
In the early nineties, Hungarian molecular biologist, Gábor Somlyai, PhD recognized that the shortage of deuterium can cause significant changes in living organisms. The most important outcome of his research carried out with deuterium-depleted water (DDW) was that tumor cells proved to be extremely sensitive to the withdrawal of deuterium (D). Deuterium depletion is a completely original approach to inhibit the growth of cancer cells in the body and according to the latest results it can also influence other physiological processes like glucose metabolism.
Recently, pharmacological industry started to develop and commercialize deuterium-containing medicines. Strategic replacement of hydrogen atoms in therapeutics with deuterium could positively influence efficacy and side effect profiles of drugs.
HYD’s approach to deuterium depletion of water and other molecules has broad potential to enhance the effectiveness of the presently available oncotherapies and result in innovative new medicines and consumer products for the treatment and prevention of cancer and other (e.g. metabolic) diseases.
HYD LLC. is marketing and distributing several products with decreased deuterium content in food and medicinal product categories. For human consumption Preventa® deuterium-depleted carbonated drinking water brand is available with different D-contents. Considering the D concentration of natural waters (140-150 ppm at our latitude), Preventa® products’ deuterium concentration varies between 125 and 45 ppm as it is indicated on the label. The products are mainly targeted on tumorous patients under conventional treatments or in remission and health-conscious consumers mostly in the age group over 40. It is made of deuterium-depleted water, natural mineral water and carbon dioxide. Preventa® is a registered trademark of HYD LLC.
VETERA-DDW-25® is medicinal preparation for veterinary use for the adjuvant therapy of neoplastic diseases of household pets. This first deuterium-depleted drug was registered in 1999. The active agent is deuterium-depleted water (DDW; 25 ppm D). Vetera-DDW-25® is mostly applied to dogs and cats suffering from cancer.
Several editions of the book „Defeating cancer!” written by Gábor Somlyai PhD are available in different languages and can be ordered from the Hungarian and foreign publishers.
You founded HYD almost 20 years ago, in 1992. Can you first explain to our readers why you made the switch from doing research at the Hungarian Institute of Oncology…
Providing universal health coverage to the nation’s roughly 10 million citizens, Hungary’s National Health Insurance Fund (OEP) has one of the most comprehensive and complex structures in Europe. The organization’s…
Chronic underfinancing is a common pitfall for many former socialist states and Hungary is no exception. Total health spending ultimately accounted for 8.0 percent of GDP in Hungary in 2014, which…
Mylan Hungary’s Tamas Uri discusses transitioning into both a branded and generic business dedicated company, Mylan’s expansion in Hungary, and how the pharmaceutical industry can be a key player in improving the…
Hungary’s Minister of Foreign Affairs and Trade Péter Szijjártó highlights the significant role that foreign direct investments have played in developing the country’s healthcare and life science sector, while detailing…
György Bodoky, Head of the Oncology Department at Unified Szent István and Szent László Hospital, shares his insights on the state of oncological care in Hungary, the current effects of…
János Burovincz, Managing Director of Patent, shares his insights on building a company from scratch, the importance of maintaining a diverse portfolio that can quickly adapt to market needs as…
GSK Hungary’s Claire Roger discusses the value of ethical promotion both in improving transparency and benefiting all stakeholders. She further describes the strategic role and economic impact of GSK’s vaccine plant in…
Róbert Ésik, President of the Hungarian Investment Promotion Agency (HIPA), shares his insights into what makes Hungary such an attractive destination for foreign direct investment and ways that the agency…
To effectively reform old habits requires diligence, consistency and, above all, patience. As an introduction for our readers, could you describe the initial objectives that you set for yourself…
Veronika Ferencz, Sales and Marketing Director for Exeltis Hungary, discusses the evolving and expanding footprint of the company in Hungary, the challenges strict regulations on food supplements are causing, as…
The leadership of Meditop discuss their history as the first non-privatized, private Hungarian pharmaceutical company, their ongoing strategies for growth in the country, and their evolving portfolio abroad. They also…
The recently appointed CEO of Servier Hungary, Dr. Jan Frederic Kesselhut highlights his initial perceptions of the Hungarian pharmaceutical market and depicts the significant role that the Servier Research Institute…
See our Cookie Privacy Policy Here